
    the study have difficulty in recruiting subjectes
  
['non-small cell lung cancer']
['paclitaxel and carboplatin regimen']

        Inclusion Criteria:

          -  Age: 18 ~75 years

          -  Pathology: Confirmed by pathology (histology or cytology) for advanced non-small cell
             lung cancer

          -  Have indications of paclitaxel/carboplatin chemotherapy, suitable for paclitaxel
             chemotherapy (independent of clinical tumor stage or chemotherapy type or palliative
             chemotherapy lines)

          -  At least one measurable tumor lesions (according to RECIST 1.1 criteria)

          -  ECOG PS score: 0 to 2 points

          -  Life expectancy: more than 3 months

          -  Bone marrow reserve function is good, the function of organs (liver and kidney) is
             good, can satisfy the conditions of implementation chemotherapy. neutrophil count
             ≥1.5×109/l, platelet ≥75×109/l, hemoglobin >9g/dl, Total Bilirubin ≤1.5×ULN*,
             transaminase <2.5×ULN*, creatinine ≤1.5×ULN*,or creatinine clearance rate ≥45ml/min.
             ULR: Upper Limit Of Normal.

          -  Sign the informed consent form; Compliance is good, can be followed up, willing to
             comply with the requirements of the study

        Exclusion Criteria:

          -  ECOG Performance Scores > 2 points

          -  Organic disease (heart, liver, kidney disease etc), Active infection Organ
             transplantation immunosuppressive therapy, not capable to complete 4 - 6 cycles of
             paclitaxel / carboplatin chemotherapy.

          -  Any other tumor history not cured in 3 years before this trial.

          -  Bone marrow function or organs function not eligible for chemotherapy.

          -  Diabetic patients currently receiving the standard anti- diabetes treatment.
      